pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
P160929J
Approved · small molecule · Community acquired pneumonia (CAP)
P160929J for Community acquired pneumonia (CAP) is a Approved program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code P160929J
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Community acquired pneumonia (CAP)
- Status
- active
- Trials
- 1